FCGR2A and neoplasm: Besides inhibition of EGFR tyrosine phosphorylation and the subsequent downstream signaling, the human IgG1 Fc portion of cetuximab can activate NK cell-mediated antibody dependent cell-mediated cytotoxicity (ADCC) in a Fc-gamma receptor (FcγR)-dependent manner [5], triggering enhanced antigen presentation and resulting in an adaptive tumor-specific immune response [6].